Lung cancer is the most common cancer worldwide and non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Substantial unmet medical need exists in this patient population, and the survival advantage of different regimens has, historically, been small. Thus, detection of therapeutic impact that can palliate potentially debilitating symptoms is critical. The NSCLC Working Group is developing a symptom inventory (i.e., Non-Small Lung Cancer Symptom Assessment Questionnaire [NSCLC-SAQ]) for qualification by the FDA for use in supporting labeling claims of treatment benefit.
Working Group Sponsors
Boehringer Ingelheim Pharmaceuticals, Inc.
Eli Lilly and Company
Janssen Pharmaceutical Companies of Johnson & Johnson
Merck, Sharp & Dohme Corp.
Novartis Pharmaceutical Corporation